CERC vs. SRRA, LXRX, SBBP, ASMB, SLGL, ALPN, NUVL, ALKS, PRGO, and CRNX
Should you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Sierra Oncology (SRRA), Lexicon Pharmaceuticals (LXRX), Strongbridge Biopharma (SBBP), Assembly Biosciences (ASMB), Sol-Gel Technologies (SLGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.
Sierra Oncology (NASDAQ:SRRA) and Cerecor (NASDAQ:CERC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
In the previous week, Sierra Oncology's average media sentiment score of 0.16 beat Cerecor's score of 0.00 indicating that Cerecor is being referred to more favorably in the news media.
Sierra Oncology received 116 more outperform votes than Cerecor when rated by MarketBeat users. However, 74.00% of users gave Cerecor an outperform vote while only 67.49% of users gave Sierra Oncology an outperform vote.
99.3% of Sierra Oncology shares are owned by institutional investors. Comparatively, 62.8% of Cerecor shares are owned by institutional investors. 44.1% of Sierra Oncology shares are owned by insiders. Comparatively, 45.7% of Cerecor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Sierra Oncology has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Sierra Oncology has a net margin of 0.00% compared to Sierra Oncology's net margin of -1,194.82%. Cerecor's return on equity of -111.88% beat Sierra Oncology's return on equity.
Cerecor has higher revenue and earnings than Sierra Oncology. Cerecor is trading at a lower price-to-earnings ratio than Sierra Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Sierra Oncology and Cerecor tied by winning 7 of the 14 factors compared between the two stocks.
Get Cerecor News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
